{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:15:55Z","timestamp":1764936955460},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,19]]},"DOI":"10.18632\/oncotarget.23629","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T15:04:39Z","timestamp":1514041479000},"page":"5823-5833","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy"],"prefix":"10.18632","volume":"9","author":[{"given":"Seung-Hwan","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Hematology, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Yeon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Incheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Sung","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary\u2019s Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","article-title":"Successful engraftment of T-cell-depleted haploidentical \u201cthree-loci\u201d incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum","volume":"84","author":"Gambelunghe","year":"1994","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Hoglund","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Lowenberg","year":"2015","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.clml.2011.02.003","article-title":"Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry","volume":"11","author":"Juliusson","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood-2010-11-321737","article-title":"Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment","volume":"117","author":"Juliusson","year":"2011","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Wheatley","year":"2007","journal-title":"Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"Raffoux","year":"2014","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.28113","article-title":"Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia","volume":"119","author":"Stockman","year":"2013","journal-title":"Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Hills","year":"2013","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Muus","year":"2016","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Feldman","year":"2014","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Bernal del Castillo","year":"2015","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.leukres.2013.03.005","article-title":"Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China","volume":"37","author":"Wang","year":"2013","journal-title":"Leuk Res"},{"key":"16","first-page":"341","article-title":"Etoposide-cytarabine therapy for acute leukemia following myelodysplastic syndromes or secondary to treatment for malignant diseases","volume":"72","author":"Bernasconi","year":"1987","journal-title":"Haematologica"},{"key":"17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0014-2964(75)90099-7","article-title":"Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213","volume":"11","author":"Roberts","year":"1975","journal-title":"Eur J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/1097-0142(19910101)67:1+<315::AID-CNCR2820671318>3.0.CO;2-S","article-title":"Future directions for etoposide therapy","volume":"67","author":"Greco","year":"1991","journal-title":"Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.23576","article-title":"Outcomes of elderlyacute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status","volume":"88","author":"Kim","year":"2013","journal-title":"Am J Hematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1634\/theoncologist.2015-0298","article-title":"The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use","volume":"21","author":"Pignatti","year":"2016","journal-title":"Oncologist"},{"key":"21","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/jco.2008.26.15_suppl.7006","article-title":"Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission","volume":"26","author":"Beach","year":"2008","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Russell","year":"2013","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Heil","year":"2012","journal-title":"Haematologica"},{"key":"24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2016.01.014","article-title":"Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis","volume":"42","author":"Zebisch","year":"2016","journal-title":"Leuk Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Angulo-Gonzalez","year":"2007","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40266-015-0285-6","article-title":"Management of Relapsed\/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments","volume":"32","author":"Jabbour","year":"2015","journal-title":"Drugs Aging"},{"key":"27","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Lowenberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Gachard","year":"2011","journal-title":"Leukemia"},{"key":"29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s002770050163","article-title":"Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study","volume":"72","author":"Lechner","year":"1996","journal-title":"Ann Hematol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3109\/10428194.2015.1091931","article-title":"Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms","volume":"57","author":"Yu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1479-5876-12-167","article-title":"Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target","volume":"12","author":"Tong","year":"2014","journal-title":"J Transl Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Biondi","year":"2003","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Storer","year":"2005","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Rubin","year":"2003","journal-title":"Semin Radiat Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:15:18Z","timestamp":1589022918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,23]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1,19]]}},"alternative-id":["23629","29464037"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23629","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,23]]}}}